Brief: Helix Biopharma presents topline L-DOS47 results
06/12/2016 13:37
Dec 6 (Reuters) - Helix Biopharma Corp HBP.TO -
* Phase I/II dose escalation study of immunoconjugate
l-dos47 as a monotherapy in non-squamous non-small cell lung
cancer patients
* Helix Biopharma Corp. Presents topline l-DOS47 results
Source text for Eikon: ID:nMKWQCbNCa
Further company coverage: HBP.TO
((Bangalore.newsroom@thomsonreuters.com))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020